(Q34184046)

31 July 2017

1 reference

title

Telaprevir: an NS3/4A protease inhibitor for the treatment of chronic hepatitis C. (English)

1 reference

31 July 2017

1 reference

Lisa S Smith

1

1 reference

31 July 2017

Michael Nelson

series ordinal

2

1 reference

31 July 2017

Sagar Naik

series ordinal

3

1 reference

31 July 2017

Joanna Woten

series ordinal

4

1 reference

31 July 2017

language of work or name

English

0 references

publication date

10 May 2011

1 reference

Annals of Pharmacotherapy

31 July 2017

1 reference

31 July 2017

45

1 reference

31 July 2017

5

1 reference

31 July 2017

639-648

1 reference

The prevalence of hepatitis C virus infection in the United States, 1999 through 2002

31 July 2017

1 reference

Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States

21 January 2018

1 reference

Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease

21 January 2018

1 reference

Diagnosis, management, and treatment of hepatitis C: an update

21 January 2018

1 reference

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

The cell biology of hepatitis C virus

21 January 2018

1 reference

The efficacy and safety of telaprevir - a new protease inhibitor against hepatitis C virus

21 January 2018

1 reference

Subcellular localization, stability, and trans-cleavage competence of the hepatitis C virus NS3-NS4A complex expressed in tetracycline-regulated cell lines

21 January 2018

1 reference

Advances in the development of new therapeutic agents targeting the NS3-4A serine protease or the NS5B RNA-dependent RNA polymerase of the hepatitis C virus

21 January 2018

1 reference

Telaprevir: a promising protease inhibitor for the treatment of hepatitis C virus infection.

21 January 2018

1 reference

Evasion of intracellular host defence by hepatitis C virus

21 January 2018

1 reference

HCV-NS3 inhibitors: determination of their kinetic parameters and mechanism

21 January 2018

1 reference

VX-950, a Novel Hepatitis C Virus (HCV) NS3-4A Protease Inhibitor, Exhibits Potent Antiviral Activities in HCV Replicon Cells

21 January 2018

1 reference

Genetic diversity and evolution of hepatitis C virus--15 years on

21 January 2018

1 reference

Molecular basis of telaprevir resistance due to V36 and T54 mutations in the NS3-4A protease of the hepatitis C virus

21 January 2018

1 reference

Resistance to direct antiviral agents in patients with hepatitis C virus infection

21 January 2018

1 reference

Amino acid substitutions in the hepatitis C virus core region of genotype 1b affect very early viral dynamics during treatment with telaprevir, peginterferon, and ribavirin.

21 January 2018

1 reference

The Hepatitis C Virus Replicon Presents a Higher Barrier to Resistance to Nucleoside Analogs than to Nonnucleoside Polymerase or Protease Inhibitors

21 January 2018

1 reference

Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects

21 January 2018

1 reference

Naturally occurring NS3-protease-inhibitor resistant mutant A156T in the liver of an untreated chronic hepatitis C patient

21 January 2018

1 reference

Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients

21 January 2018

1 reference

GT-1a or GT-1b Subtype-Specific Resistance Profiles for Hepatitis C Virus Inhibitors Telaprevir and HCV-796

21 January 2018

1 reference

Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C.

21 January 2018

1 reference

Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients

21 January 2018

1 reference

Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir

21 January 2018

1 reference

Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study

21 January 2018

1 reference

Pharmacokinetic enhancement of the hepatitis C virus protease inhibitors VX-950 and SCH 503034 by co-dosing with ritonavir

21 January 2018

1 reference

Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients

21 January 2018

1 reference

Rapid loss of hepatitis C virus genotype 1b from serum in patients receiving a triple treatment with telaprevir (MP-424), pegylated interferon and ribavirin for 12 weeks.

21 January 2018

1 reference

Sustained virological response in a patient with chronic hepatitis C treated by monotherapy with the NS3-4A protease inhibitor telaprevir

21 January 2018

1 reference

Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection

21 January 2018

1 reference

Telaprevir and peginterferon with or without ribavirin for chronic HCV infection

21 January 2018

1 reference

Telaprevir for previously treated chronic HCV infection

21 January 2018

1 reference

Telaprevir: a new hope in the treatment of chronic hepatitis C?

21 January 2018

1 reference

Acceptance of telemonitoring to enhance medication compliance in patients with chronic heart failure.

21 January 2018

1 reference

New directly acting antivirals for hepatitis C: potential for interaction with antiretrovirals.

21 January 2018

1 reference

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.1P430

1 reference

31 July 2017

1 reference